Can Calquence Precipitate Gout?
No, there is no established evidence that Calquence (acalabrutinib) directly precipitates gout, though one case report suggests a possible association with ibrutinib, a related BTK inhibitor.
Evidence from FDA Drug Label
The FDA prescribing information for Calquence does not list gout or hyperuricemia as adverse reactions in the comprehensive safety data from 1,764 patients 1. The most common adverse reactions (≥30%) were diarrhea, upper respiratory tract infections, headache, musculoskeletal pain, lower respiratory tract infections, and fatigue—but gout was not reported 1.
Notably, the drug label does mention uric acid increased as a laboratory abnormality:
- In the ECHO trial (MCL patients): 45% had uric acid elevation (all Grade 3-4) with acalabrutinib plus bendamustine/rituximab, compared to 40% with placebo 1
- In the ASCEND trial (CLL patients): 15% had uric acid increase (all Grade 3-4) 1
However, these elevations appear to be related to tumor lysis syndrome risk rather than drug-induced hyperuricemia leading to gout. The label specifically warns about tumor lysis syndrome as a serious adverse reaction 1.
Limited Case Report Evidence
One case report describes a 65-year-old CLL patient who developed bilateral first MTP joint gout flare four months after starting ibrutinib (a different BTK inhibitor), despite being compliant with allopurinol prophylaxis 2. This is notable because:
- The patient was already on allopurinol with >99% compliance
- The mechanism remains unclear
- This was ibrutinib, not acalabrutinib
- This represents a single case report, the lowest level of evidence
Clinical Context and Interpretation
The uric acid elevations seen with Calquence appear to be tumor-related (from tumor lysis) rather than drug-induced hyperuricemia:
- Tumor lysis syndrome is explicitly mentioned in the Calquence safety profile 3
- The uric acid increases occur in the context of hematologic malignancy treatment where rapid cell turnover releases intracellular contents
- This is mechanistically different from drugs that impair renal uric acid excretion (like diuretics) or increase uric acid production 4
If a patient on Calquence develops gout, consider:
- Pre-existing gout risk factors (age, male gender, obesity, hypertension, alcohol use) 5
- Tumor lysis syndrome if occurring early in treatment with high tumor burden 3
- Concomitant medications that truly cause hyperuricemia (diuretics, low-dose aspirin) 5
- Natural disease progression of underlying gout unrelated to Calquence
Management Approach
If gout occurs in a patient on Calquence:
- Treat the acute flare with colchicine, NSAIDs, or corticosteroids per standard guidelines 5, 6
- Do not discontinue Calquence unless tumor lysis syndrome is suspected
- Initiate or optimize urate-lowering therapy (allopurinol) if indicated by gout severity 5
- Monitor for tumor lysis syndrome if early in treatment course, especially with high disease burden 3
Bottom line: Calquence does not appear to be a gout-precipitating drug based on extensive clinical trial data, though vigilance for tumor lysis-related hyperuricemia is warranted.